Molecular targeting drug-entrapped liposome and application of liposome in preparation of drug for treating tumors

Abstract

The invention belongs to the field of biological medicines, and relates to a molecular targeting drug-entrapped liposome and application of the liposome in preparation of a drug for treating tumors. The molecular targeting drug-entrapped liposome is composed of a molecular targeting drug, and lipidosome components such as phospholipid, cholesterol, mPEG-DSPE and/or targeting molecule modified PEG-DSPE. The liposome is prepared by loading a molecular targeting drug into a water phase or phospholipid bilayer in a liposome in an active or passive drug loading manner so that tumor targeting drug delivery can be realized, and the anti-tumor effect, especially the anti-brain tumor effect, of the molecular targeting drug is remarkably enhanced. Furthermore, the combination of the molecular targeting drug-entrapped liposome and pharmaceutically acceptable medicinal components and/or diluents can be prepared into various dosage forms for targeting treatment of tumors and has potential clinicalapplication value.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a liposome carrying molecular targeting drugs and its application in preparing drugs for treating tumors. Background technique [0002] The prior art discloses that molecular targeted drugs are mainly targeted at the key targets of malignant tumor occurrence and development for therapeutic intervention. Because they can selectively kill tumor cells, they have good tolerance and low toxicity. Compared with traditional cytotoxic drugs Anticancer drugs have greater advantages. According to reports, some molecular targeted drugs have shown better efficacy in the corresponding tumor treatment. Molecular targeted drugs can be divided into single-target inhibitors and multi-target inhibitors. Currently known single-target inhibitors include BCr-Abl kinase inhibitors (such as imatinib, dasatinib, ponatinib, etc.) Ni, etc.), epidermal growth factor (EGFR) inhibitors (such as gefit...

AI Technical Summary

Problems solved by technology

Known multi-target inhibitors such as AL3180, sunitinib, regoratinib, sorafenib, vandetanib, cabozantinib, lenvatinib, pazopanib, vemurafenib , axitinib, dabrafenib, linivarib, nintedanib, etc.; some studies have reported that the poor solubility of most molecularly targeted drugs affects their bioavailability, or it is difficult to penetrate biological barriers (such as Blood-brain barrier BBB, blood-tumor barrier BTBB, etc.) affect its curative effect on brain tumors and some solid tumors

Images